|
Vaxart Inc (NASDAQ: VXRT) |
|
Vaxart Inc
VXRT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Vaxart Inc growth rates, revenue grew
by 134.79 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 126
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.29 %
Vaxart Inc net loss decreased from $-17 millions, to $-14 millions in III. Quarter 2024,
• More on VXRT's Growth
|
|
Vaxart Inc realized a net loss in trailing twelve months.
Vaxart Inc realized cash reduction of $ -0.05 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 8.28.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.38.
• More on VXRT's Valuation
|
|
|
|
|
Vaxart Inc realized net loss in trailing twelve months.
Vaxart Inc realized cash outflow of $ -0.05per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 8.28.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.38.
Vaxart Inc Price to Book Ratio is at 2.03 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.01
• More on VXRT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com